Interstitial Cystitis

Interstitial Cystitis / Bladder Pain Syndrome: A Natural-Health and Nutritional Reference

1. Definition and Nomenclature

Interstitial cystitis/bladder pain syndrome (IC/BPS), formerly called interstitial cystitis, is a chronic (greater than six weeks in duration) pelvic condition that affects or appears to affect the urinary bladder with symptoms of discomfort, pressure, or pain. The condition is characterized by chronic inflammation and lower urinary tract symptoms, not due to infection or any other clearly identifiable cause. In many cases, because IC/BPS remains a diagnosis of exclusion, the condition is often identified late or misdiagnosed, particularly in men, as chronic prostatitis/chronic pelvic pain syndrome or overactive bladder.

It is now broadly agreed that IC is a multifactorial syndrome, not a single condition. A variety of etiologies have been proposed, but none has been definitively proven. The American Urological Association (AUA) definition is widely used in clinical and research settings.

2. How It Presents: Signs, Symptoms, and Clinical Features

Generally agreed diagnostic criteria of this condition, which occurs primarily in females, are frequency, urgency and pain, a low-capacity hypersensitive bladder, and mucosal haemorrhages and tearing on bladder distention. Symptoms include urinary frequency and urgency, pain, dyspareunia, and nocturia.

Interstitial cystitis, or painful bladder syndrome, can present with lower abdominal pain/discomfort and dyspareunia, and pain in any distribution of lower spinal nerves. IC/BPS denotes a range of persistent urological symptoms predominantly marked by pain or pressure in the suprapubic region. These symptoms are often associated with heightened urine frequency, urgency, and/or nocturia, occurring without infection or other identifiable clinical abnormalities.

IC/BPS is categorized into Hunner (ulcerative) type IC/BPS or non-Hunner (nonulcerative) type IC/BPS. Hunner IC/BPS is defined by the presence of Hunner's lesions (mucosal lesions accompanied by abnormal capillary structures) and is characterized by more severe bladder symptoms such as urothelial denudation, inflammation, immune cell infiltrates, edema, and reduced bladder capacity. Non-Hunner IC/BPS has no obvious bladder etiology, features minimal histological changes, and is more often accompanied by non-urologic systemic comorbidities including fibromyalgia and irritable bowel syndrome that contribute to widespread pain beyond the bladder.

Individuals with IC/BPS exhibit a higher incidence of stress, sleep disturbances, depression, and sexual dysfunction compared to the general population, resulting in a substantially greater impairment in quality of life.

2.1 Epidemiology

The prevalence of IC/PBS is estimated to be in the range of 45 per 100,000 women and 8 per 100,000 men, whereas joint prevalence in both sexes is 10.6 cases per 100,000. The ailment primarily impacts women aged 40 to 60, with an estimated prevalence of 3 to 8 million females and more than 2 million males diagnosed with bladder pain syndrome in the United States. Onset is predominantly in adulthood although IC does occur in childhood.

2.2 Diagnosis

A precise diagnosis necessitates a comprehensive clinical history, the presence of sterile urine with negative cytology, cystoscopic hydrodistention performed under anesthesia, and histopathological evaluation of bladder biopsy samples. Bladder biopsies from patients with IC/BPS show increased numbers of mast cells, alterations in interstitial cells, infiltration of inflammatory cells, edema, fibrosis, and vascular lesions.

3. Body Systems Involved

3.1 The Urothelium and Glycosaminoglycan (GAG) Layer

In the normal healthy bladder the urothelium forms the luminal interface with the urinary solutes generating a functionally tight urothelial barrier that restricts the movement of solutes into the underlying tissues. Damage to the urothelial layer leads to leakiness and increased permeability, allowing solutes to permeate into the sub-urothelium, which is a key factor in disease pathophysiology. The barrier function of the urothelium is associated with a thick mucus coating consisting of a variety of proteoglycans, composed of a protein core and negatively charged glycosaminoglycan (GAG) side chains.

In IC, damage occurs to the mucous or glycosaminoglycans layer, causing altered permeability of the urothelium to various urinary cations such as potassium. These etiological factors lead to urothelium damage and leakage of urine solutes, especially potassium salts, into the lamina propria, resulting in hypersensitivity of the neurons and, ultimately, pain.

3.2 The Immune System and Mast Cells

Several hypotheses have been suggested concerning the pathophysiology of IC/BPS, including epithelial failure, mast cell activation, neurogenic inflammation, autoimmune response, and latent infection. These mechanisms are not mutually exclusive. Rather, they may engage within a multifaceted network that collectively contributes to the initiation and advancement of the disease.

The inflammatory cells in bladder biopsies consist of lymphocytes and plasma cells distributed mostly in the suburothelial region. Lymphoid aggregates/follicles were observed in approximately 40% of IC/BPS patients. Moreover, few eosinophils and neutrophils were found in the bladder tissue. The superficial layer of urothelium is lost and urothelial denudation was often observed.

3.3 The Nervous System

Important elements of the disease process include increased afferent and efferent neuronal activity, an excess of inflammatory mediators, increased epithelial permeability and possibly reduced bladder vascularity. The neuropeptides CGRP and SP may play a role in urinary bladder afferent pathways following chronic urinary bladder inflammation. Changes in CGRP or SP expression following cystitis may contribute to altered visceral sensation (allodynia) and/or urinary bladder hyperreflexia.

Increased levels of nerve growth factor (NGF) and morphological changes (neuroplasticity) in sensory and motor neurons may be responsible for continued pain, frequency, and urgency even after the initial inflammatory stimulus has subsided. A hallmark of functional pain syndromes such as IC/BPS is pain in the absence of demonstrable pathology of the viscera or associated nerves.

3.4 The Autonomic Nervous System and Stress Axis

Stress may exacerbate IC symptoms due to release of corticotropin-releasing factor (CRF) and subsequent activation of mast cells. Various etiological factors are implicated in the pathogenicity of IC/BPS, such as inflammation, neuropathy, injury to the urothelium and disturbance in its function, damage of the glycosaminoglycan layer, mast cell activation, and autoimmune disorders. Additionally, stress or chronic stress strongly contributes to the occurrence, aggravation, and pathogenicity of IC/BPS.

3.5 The Oxidative Stress System

Recent research has highlighted chronic inflammation and oxidative stress, resulting from either increased production of reactive oxygen species or their inadequate elimination, as a significant feature of IC/BPS. The frequent co-occurrence of IC/BPS with other chronic diseases characterized by prolonged oxidative stress and subtle chronic inflammation, such as autoimmune diseases, chronic psychological stress, fibromyalgia, and irritable bowel syndrome, suggests a common underlying pathogenic pathway.

4. Contributing and Associated Factors

4.1 Proposed Etiological Mechanisms

Chronic bacterial infection, defective glycosaminoglycan (GAG) layer of the bladder urothelium, inappropriate activation of mast cells in the suburothelial layer of the bladder, autoimmune-mediated mechanisms, and autonomic nervous system dysfunction have all been implicated.

Investigated hypotheses for causative factors include occult or resistant microorganisms, urothelial hyperpermeability, neurogenic or hormonal pathomechanisms, and mast cell activation. Researchers previously identified an interstitial cystitis urine factor, antiproliferative factor, that inhibits proliferation of bladder epithelial cells in vitro and causes complex changes in epithelial growth factor levels, including profound decreases in heparin-binding epidermal growth factor-like growth factor (HB-EGF). Bladder and renal pelvic catheterization of patients with interstitial cystitis indicated that the antiproliferative factor is made and/or activated in the distal ureter or bladder.

4.2 Psychological Factors and Adverse Life Events

This altered stress response, characterized by increased cytokines and lack of a cortisol response, could contribute to the signs often noted in IC patients—urinary urgency, frequency, bladder or voiding pain, and painful intercourse—supporting the importance of adverse life events as risk factors for IC via a biological mechanism.

IC/BPS is associated with lower pain threshold and higher depression levels, after controlling for known confounding factors. A history of PTSD appears to increase the severity of IC/PBS symptoms.

4.3 Comorbid Conditions

IC/BPS symptoms can frequently overlap with other conditions including irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, anxiety disorders, and a number of other syndromes not directly related to the urinary bladder. In patients with IC/BPS, the presence of fibromyalgia, chronic fatigue syndrome, and IBS has a significant association with health-related quality of life, equivalent in impact to the bladder symptoms themselves.

This finding is consistent with previous studies linking fibromyalgia and interstitial cystitis as shared comorbidities with possible shared pathophysiology. Research has typically emphasized the bladder's role, but given the high presence of systemic comorbidities, a pathophysiologic nervous system role has been hypothesized.

5. Dietary and Nutritional Factors

5.1 Overview of the Diet–Symptom Relationship

IC/BPS is characterized by pelvic pain, pressure, or discomfort in the bladder and pelvic area coupled with urinary frequency and urgency. The cause is unknown. Dietary intake appears to exacerbate IC/BPS symptoms for many patients; however, the association is not well understood.

The collective evidence from reviewed studies confirms the importance of dietary influence on IC/BPS symptom management. An individualized approach to dietary counseling based on patient sensitivities could be beneficial. However, the diversity in study methodologies and outcomes indicates a need for more uniform research to establish standardized dietary guidelines for IC/BPS patients.

5.2 Dietary Trigger Foods

One of the most replicated findings in IC/BPS research concerns the role of specific foods and beverages in provoking symptom flares. In a web-based questionnaire study with 598 complete responses, 95.8% of participants answered that certain foods and beverages affected their IC/BPS symptoms. Most items had no effect on symptoms. Items that made symptoms worse were citrus fruits, tomatoes, coffee, tea, carbonated and alcoholic beverages, spicy foods, artificial sweeteners, and vitamin C.

In a nationwide cohort of Veterans with IC/BPS, 70% had one or more food sensitivities versus 37% of those with other pelvic pain conditions and 32% of healthy controls. The average number of sensitivities were significantly greater in IC/BPS patients than in either comparison group.

The long-held notion is that patients with IC should avoid acidic foods. This logic is largely based on anecdotal data and questionnaires of foods, beverages, and supplements that increase symptoms. Controversy exists that the IC diet restricts many more foods than necessary. A thorough literature review did not find analytical studies that correlated diet with IC symptoms or that demonstrated that ingestion of acidic foods exacerbates IC symptoms. This highlights the predominantly observational nature of the dietary evidence base.

It is recommended that patients with IC/BPS consider avoiding citrus fruits, tomatoes, coffee, tea, carbonated and alcoholic beverages, spicy foods, artificial sweeteners, and vitamin C. The use of calcium glycerophosphate and/or sodium bicarbonate before consumption of these trigger consumables may also help reduce sensitivity.

5.3 Anti-Inflammatory Dietary Patterns

The Anti-Inflammatory Diet for Interstitial Cystitis (AID-IC) study employed a randomized, crossover design to evaluate the effect of a plant-based, low saturated fat diet on the quality of life of women with IC/BPS. The logistics of the protocol proved time-consuming; however, the barriers were surmountable. Quantitative and qualitative findings suggest that the AID-IC therapeutic diet may have lessened symptoms and improved the quality of life for many of the women in the study.

This 2022 pilot study was conducted by researchers at Idaho State University and collected data using three validated instruments: the 9-item Genitourinary Pain Index (GUPI), 19-item Female Sexual Functioning Inventory (FSFI), and 6-item RAND Interstitial Cystitis Epidemiology (RICE) Bladder Symptom Impact Scale. Blood samples were collected to evaluate inflammatory markers including tumor necrosis factor (TNF)-α, interleukin (IL)-1, and C-reactive protein. The study remains preliminary; its design is a pilot and broader trials with larger samples are needed before firm dietary recommendations can be standardized.

5.4 Urinary pH and Food Acidity

Current questionnaire-based data suggest eliminating tomatoes, citrus fruits, vitamin C, artificial sweeteners, carbonated and alcoholic beverages, and spicy foods, which are thought to exacerbate symptoms, while calcium glycerophosphate and sodium bicarbonate may improve symptoms. The hypothesis underpinning avoidance of acidic foods is that lowering urinary pH may reduce irritation of the already-compromised urothelial barrier. However, as noted above, no controlled analytical studies have directly confirmed a urine-pH–to–symptom relationship.

6. Nutrients, Herbs, and Natural Ingredients

6.1 Quercetin

Traditional Use

Quercetin is present in a number of fruits and vegetables, such as apple, onion, celery, and chilli pepper. It is a dietary flavonoid consumed broadly across cultures wherever these foods form part of the traditional diet. No specific historical ethnobotanical preparation targeted at bladder conditions has been documented in classical herbal monographs. Its use in urological conditions is largely a modern phytochemical application driven by mechanistic research.

Scientific Evidence

Quercetin (QCT), whose chemical name is 3,5,7,3′,4′-pentahydroxy flavone, is a natural flavonoid compound. Quercetin has chemical preventive and therapeutic effects on many diseases, and its activities are shown as antioxidant, anticancer, antihypertensive, antidiabetic, anti-inflammatory, antiviral, and neuroprotective. Quercetin demonstrates an ability to inhibit mast cells and pro-inflammatory cytokines and regulate cell proliferation.

A small open-label clinical study (Katske et al., 2001, published in Techniques in Urology, PMID 11272677) evaluated a quercetin-based supplement (Cysta-Q) in patients with IC. In a study of 22 patients with interstitial cystitis, a quercetin-based supplement taken for 4 weeks led to significant improvements in symptoms, with all patients reporting some level of improvement and no negative side effects observed. The treatment resulted in substantial reductions in problem and symptom indices, as well as pain assessment scores.

This small study showed that patients who took 500 mg of quercetin twice daily for just four weeks experienced improvement in IC urinary symptoms and pain scores. These studies suggest that quercetin alone or combined with other therapy might be a treatment option for IC/BPS, especially for refractory IC/BPS. However, a prospective, randomized, placebo-controlled trial is needed to provide strong evidence for the efficacy of quercetin.

Evidence strength: Preliminary. The available human evidence rests on a single small open-label, uncontrolled study. No randomized, double-blind, placebo-controlled trials in IC specifically have been published as of the current literature. The mechanistic basis (mast cell inhibition, anti-inflammatory cytokine modulation) is supported by in vitro and animal data.

6.2 Oral Aloe Vera (Aloe barbadensis)

Traditional Use

Aloe vera has a long history of use across multiple traditional systems—Egyptian, Greek, Ayurvedic, and indigenous Mesoamerican—primarily as a topical agent for wound healing and skin inflammation. Its oral use for internal mucosal conditions is a more recent development, with application to bladder conditions emerging in clinical settings from the 1990s onward.

Scientific Evidence

Concentrated aloe vera has been used by thousands of patients to reduce the symptoms of interstitial cystitis. Though the mechanism of action has not been proven, it is hypothesized that the ability of aloe vera to increase the body's production of glycosaminoglycan (GAG) molecules—which has been demonstrated in the healing of wounds—may also increase GAG synthesis in the bladder lining. Orally administered aloe vera has been demonstrated in preclinical studies to increase the body's synthesis of GAG molecules by 43%.

An initial double-blind placebo-controlled study, although small, had an 87.5% response rate of some or complete relief of all symptoms with aloe vera capsules. This preliminary study originated from The Urology Wellness Center in 1995. A more rigorous double-blind, placebo-controlled study has been designed to establish the safety and efficacy of super-concentrated, freeze-dried aloe vera in the management of the symptoms of interstitial cystitis. This would be the first double-blind, placebo-controlled study that specifically addresses safety and efficacy as primary endpoints in patients with IC.

Some nutraceuticals including calcium glycerophosphate and aloe vera extract were reported to be helpful for some cases. However, due to lack of efficacy supported by substantial clinical evidence, these nutrition supplements are not used widely in clinical practice.

Evidence strength: Weak to preliminary. Preclinical data support a plausible GAG-synthesis mechanism, and survey data are suggestive, but the only published controlled human data consist of a small unpublished pilot. A formal Phase 2 trial is currently registered at ClinicalTrials.gov (NCT04734106) and its completion will provide the first rigorous safety and efficacy data.

6.3 L-Arginine

Traditional Use

L-arginine is a conditionally essential amino acid found abundantly in dietary protein sources such as red meat, poultry, fish, dairy, and nuts. It has not been used in any formal traditional botanical or Ayurvedic context specifically for bladder conditions; its application in IC derives entirely from modern pharmacological hypotheses concerning nitric oxide synthesis.

Scientific Evidence

Some individuals with IC consider arginine supplementation due to its potential vasodilatory effects and its involvement in nitric oxide synthesis, which can impact bladder function. Although evidence is limited, several studies have reported positive benefits. One study reported increased urinary nitric oxide-related enzymes and metabolites, combined with reduced IC symptoms, with long-term L-arginine supplementation dosed 1,500 mg daily for six months.

Two open-label uncontrolled trials found 1.5 grams L-arginine daily for six months increased urinary nitric oxide synthase activity and reduced IC/BPS symptoms. However, in one report, no positive effects were seen in nine IC/BPS patients given either 3 grams or 10 grams of L-arginine per day for five weeks. An intent-to-treat analysis did not show any notable difference between L-arginine and placebo group. Because most of these studies had small sample sizes, the reported outcomes become controversial and the efficacy of L-arginine and the effect of nitric oxide on IC/BPS still deserve further study.

Evidence strength: Mixed and weak. Open-label trials suggest benefit but a formal randomized, placebo-controlled crossover trial (Cartledge et al., 2000, BJU International) did not confirm efficacy over placebo in intent-to-treat analysis. Sample sizes across all published trials are small.

6.4 Glycosaminoglycan (GAG) Molecules: Glucosamine, Chondroitin Sulfate, Hyaluronic Acid

Traditional Use

GAG precursors such as glucosamine and chondroitin sulfate have been used in traditional Chinese medicine for joint conditions. Their application to IC is a modern extension based on the biological rationale that the bladder lining's protective mucus layer is composed largely of GAG molecules.

Scientific Evidence

Chondroitin sulfate, glucosamine sulfate, and hyaluronic acid are glycosaminoglycan molecules that contribute to the protective barrier of the bladder lining. Although most research has focused on intravesical (administered directly into the bladder) use of these compounds, one uncontrolled trial in 252 subjects with IC/BPS found treatment with an oral supplement providing 600 mg chondroitin sulfate, 480 mg glucosamine sulfate, and 40 mg hyaluronic acid, plus 600 mg quercetin and 80 mg rutin per day, led to reduced symptom severity during more than 12 months of monitoring and was more effective in those who had more severe symptoms at baseline.

Intravesical glycosaminoglycan layer treatments have been investigated in numerous randomized trials and reported mechanisms of actions include repair of the defective GAG layer and reduction of neurogenic inflammation/hypersensitivity in the bladder. Variable clinical improvements have been seen with different agents, including dimethyl sulfoxide (DMSO), hyaluronic acid, chondroitin sulphate, heparin, pentosan polysulfate sodium (PPS), and lidocaine.

Evidence strength: Moderate for intravesical use (the subject of multiple randomized trials); weak for oral GAG supplementation, which rests on one uncontrolled trial with a multi-ingredient formula precluding attribution of benefit to any individual component.

6.5 Probiotics and the Gut–Bladder Axis

Traditional Use

Fermented foods containing live bacterial cultures—including yogurt, kefir, kimchi, and cultured dairy products—have been part of traditional diets in numerous cultures and used informally to support intestinal and urinary tract health. No classical monograph tradition specifically describes probiotic use for IC.

Scientific Evidence

A survey showed that 58.8% of 442 IC/BPS patients receiving probiotics reported a marked improvement based on a self-evaluation. A systematic review has confirmed the efficacy of probiotics for irritable bowel syndrome. Probiotics may be a treatment option for IC/BPS patients with comorbid IBS according to "organ cross-talk" theory.

Evidence strength: Preliminary. The evidence base for probiotics in IC specifically consists of survey data and mechanistic hypotheses linking gut microbiome diversity to bladder health. No published randomized controlled trials in IC have been identified. This is considered an emerging research area.

6.6 Quercetin in Combination: CystoProtek

CystoProtek is a multi-ingredient oral supplement containing quercetin, chondroitin sulfate, glucosamine sulfate, hyaluronic acid, and rutin. These pills contain three components that are building blocks of the bladder lining (chondroitin sulfate 150 mg, sodium hyaluronate 10 mg, and glucosamine sulfate 120 mg), while quercetin 150 mg and rutin 20 mg are anti-inflammatory flavonoids. Clinical studies of this combination, including an open-label pilot and a study in refractory IC patients (Theoharides et al., 2005 and 2008), have been published, but these are small, open-label, and uncontrolled, limiting interpretability of results.

6.7 Calcium Glycerophosphate (Prelief)

Calcium glycerophosphate is a mineral compound used as a food additive. In the IC context, it functions as an antacid, raising the pH of acidic foods and beverages prior to ingestion. Its use before consumption of trigger consumables may help reduce sensitivity in IC/BPS patients. It is not an herbal or botanical compound and has no traditional-use history predating its modern application in IC dietary management. Evidence is based on patient reports and observational data rather than controlled trials.

6.8 Corn Silk (Zea mays stigma)

Traditional Use

Corn silk—the thread-like styles of the maize plant—has been used as a folk remedy for urinary tract complaints across Native American, Chinese, and European traditions. Preparations most commonly involved decocting the dried silk in water and drinking the resulting tea for conditions including cystitis, urinary frequency, and bladder irritability.

Scientific Evidence

There is no published controlled human clinical evidence for corn silk specifically in IC/BPS. References to its use in IC appear in integrative-medicine review articles and patient community literature but are not supported by peer-reviewed trials. In vitro and animal studies have demonstrated anti-inflammatory and diuretic properties of corn silk extracts, but their relevance to IC pathophysiology in humans has not been established.

6.9 Kava (Piper methysticum)

Traditional Use

Kava has been used historically as a urinary antispasmodic and anti-inflammatory agent. It can also be used as a natural anxiolytic agent, helpful in IC cases reported to be aggravated by stress, or to support the general emotional well-being of patients. Its traditional use originates in the Pacific Islands, where kava preparations are made from the root of the plant and consumed ceremonially and medicinally. Applications to urinary conditions appear in indigenous Pacific Island practice and in earlier Western herbal traditions.

Scientific Evidence

No published clinical trials specifically evaluate kava for IC/BPS. Its anxiolytic and muscle-relaxant properties are better studied in the context of anxiety disorders. Given that stress and psychological distress are established exacerbating factors in IC, the theoretical rationale is plausible. Kava has been associated with hepatotoxicity in some reports, particularly with non-traditional preparation methods and with alcohol-based extracts; regulatory advisories have been issued in several jurisdictions.

6.10 Omega-3 Fatty Acids

Traditional Use

Fish and marine oils rich in omega-3 fatty acids have long been part of traditional diets in coastal and Arctic communities. Their use for inflammatory conditions is documented historically, though not in a context specifically targeting the bladder.

Scientific Evidence

No published randomized controlled trials have specifically investigated omega-3 supplementation for IC/BPS symptoms. The rationale for their consideration is based on general anti-inflammatory mechanisms: omega-3 fatty acids (EPA and DHA) shift eicosanoid production away from pro-inflammatory prostaglandins and leukotrienes, and chronic inflammation and oxidative stress are significant features of IC/BPS. This remains a mechanistic hypothesis without direct human trial confirmation in IC.

6.11 Vitamin D

Traditional and Modern Context

Vitamin D is obtained endogenously through solar UV-B exposure and from dietary sources (fatty fish, fortified foods, egg yolk). Its immunomodulatory roles are extensively documented across many chronic inflammatory conditions.

Scientific Evidence

The evidence for vitamin D specifically in IC/BPS is limited. No clinical trials targeting vitamin D repletion in IC have been published as indexed peer-reviewed studies. The theoretical basis for interest—that vitamin D deficiency is associated with immune dysregulation and mast cell activity, both of which are implicated in IC pathophysiology—is mechanistically plausible but has not been tested in formal trials in this population.

6.12 Magnesium

Traditional and Modern Context

Magnesium is an essential mineral involved in over 300 enzymatic reactions. Its roles in smooth muscle relaxation and modulation of neuronal excitability have motivated interest in urological conditions involving bladder spasm and visceral pain.

Scientific Evidence

A 2020 study found that normalising magnesium deficiency in a cystitis model reduced pain, depression-like behaviour, and neuroinflammation through TNF-α/NF-κB pathway inhibition. This was an animal model study. An older trial showed magnesium hydroxide helped women with sensory urgency and detrusor instability. Human clinical evidence directly in IC/BPS is lacking; the animal and related urological data provide mechanistic interest but insufficient direct evidence for IC-specific recommendations.

7. Lifestyle Factors

7.1 Stress and Psychological Factors

While an underlying etiology is unclear, the pathogenesis of IC involves neurogenic inflammation, urothelial mast cell dysfunction, and likely an autoimmune response to urothelial components. Symptom severity and presentation in IC varies with cycles of flares and remissions, which are often associated with emotional factors.

In a study of 154 women with IC and 32 healthy controls, patients with greater exposure to recent life adversity (RLA) or cumulative early life adversity and RLA of at least moderate severity had increased concentrations of a composite of all cytokines. This suggests biological pathways through which psychological stressors may translate to inflammatory bladder activity.

7.2 Pelvic Floor and Physical Activity

Bladder wall defects, autoimmune disorder, viral and/or bacterial infection, toxin exposure, pelvic floor dysfunction, and inflammatory response are possible causes of IC. Pelvic floor physical therapy is recognized in AUA clinical guidelines as a first- or second-line intervention, based on evidence from controlled trials demonstrating reductions in pelvic pain and urinary symptoms. It targets myofascial trigger points and reduces the muscular contributions to pain.

7.3 Bladder Training and Behavioral Approaches

Bladder training is a self-control technique suppressing urge to urinate, which has been listed as a first-line treatment in AUA guidelines. In one study, 71% of 21 IC/BPS patients managed with this technique reported at least 50% symptom relief.

7.4 Comorbidity Management and Multidisciplinary Approach

Recommended therapies may include diet modification, stress management, and treatment of common co-occurring conditions such as irritable bowel syndrome, fibromyalgia, panic, and depression, along with physical therapy and pain management. The presence of fibromyalgia, chronic fatigue syndrome, and IBS has a significant impact on quality of life in IC/BPS patients, equivalent in impact to the bladder symptoms themselves. These results emphasize the importance of a multidisciplinary approach to treating patients with IC/BPS and other conditions.

8. Summary of Evidence Levels

• Dietary trigger avoidance — Supported by large cross-sectional surveys (>500 patients); mechanistic basis partly explained but not confirmed by analytical studies. Evidence level: observational/moderate.
• Anti-inflammatory dietary pattern — One small randomized crossover pilot (AID-IC, 2022) with qualitative and quantitative improvement in symptoms. Evidence level: preliminary/low.
• Quercetin — One small, uncontrolled open-label trial in 22 IC patients with symptom improvement; no placebo-controlled trial in IC. Evidence level: preliminary/weak.
• L-arginine — Mixed results: two open-label positive trials; one randomized crossover trial showing no intent-to-treat benefit. Evidence level: mixed/weak.
• Oral GAG precursors (glucosamine/chondroitin/hyaluronic acid) — One uncontrolled 252-subject trial of multi-ingredient supplement. Intravesical forms better studied. Evidence level: preliminary/weak for oral.
• Aloe vera (oral) — Preclinical GAG-synthesis data; small uncontrolled pilot and patient survey data; ongoing Phase 2 RCT. Evidence level: preliminary/weak.
• Probiotics — Survey data only in IC; no RCT. Evidence level: preliminary/very weak.
• Omega-3 fatty acids, Vitamin D, Magnesium — Mechanistic rationale from basic science; no IC-specific RCTs. Evidence level: theoretical/very preliminary.
• Corn silk, Kava — Traditional use history; no IC-specific human clinical data. Evidence level: traditional use only.

References

• Kelada E, Jones A. Pathophysiology of interstitial cystitis. Arch Gynecol Obstet. 2007 — PubMed
• Interstitial cystitis review: pathophysiology, assessment, diagnosis and management — PubMed
• Hanno P. Editorial Comment: Pathophysiology of interstitial cystitis. Int J Urol. 2019 — PubMed
• Interstitial cystitis: epidemiology, pathophysiology, and clinical presentation — PubMed
• Birder L. Pathophysiology of interstitial cystitis. Int J Urol. 2019 — Wiley Online Library
• Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome — PubMed
• Interstitial Cystitis/Bladder Pain Syndrome — StatPearls, PubMed/NCBI
• Interstitial cystitis: an update — PubMed
• Interstitial cystitis: update on etiologies and therapeutic options — PubMed
• Interstitial cystitis: etiology, diagnosis, and treatment — PubMed
• Interstitial cystitis — an imbalance of risk and protective factors? — PMC
• Advances in Cytokines and Inflammatory Mechanisms in the Pathogenesis of IC/BPS — PMC
• Role of inflammation in bladder function and interstitial cystitis — PMC
• Application of Adult and Pluripotent Stem Cells in IC/BPS Therapy — PMC
• Clinical Management of Bladder Pain Syndrome/Interstitial Cystitis: A Review — PMC
• Urinary Biomarkers in IC/BPS and Its Impact on Therapeutic Outcome — PMC
• Effect of Glycosaminoglycan Replacement on Markers of Interstitial Cystitis In Vitro — PMC
• Oxidative Stress and Chronic Inflammation as Partners in Crime in IC/BPS — PMC
• Dietary consumption triggers in interstitial cystitis/bladder pain syndrome patients — PubMed
• Dietary Influence on Bladder Pain Syndrome: A Systematic Review — PMC
• Food Sensitivities in a Diverse Nationwide Cohort of Veterans with IC/BPS — PMC
• Eating, Diet, & Nutrition for Interstitial Cystitis — NIDDK/NIH
• Anti-inflammatory Diet for Interstitial Cystitis (AID-IC): Study Protocol for a Randomized Controlled Cross-Over Trial — PMC
• Anti-Inflammatory Diet for Women with Interstitial Cystitis/Bladder Pain Syndrome: The AID-IC Pilot Study — PMC
• Dietary Impact on Urinary pH in Women With Interstitial Cystitis — ClinicalTrials.gov
• Effect of comestibles on symptoms of interstitial cystitis — PubMed
• Identification of key pathways in IC/BPS treatment with quercetin through bioinformatics analysis — PMC
• The Chinese approach to complementary and alternative medicine treatment for IC/BPS — Translational Andrology and Urology
• Katske F et al. Treatment of interstitial cystitis with a quercetin supplement. Tech Urol. 2001 — PubMed
• The Implications of Mental Health and Trauma in Interstitial Cystitis — PMC
• Pelvic Floor and Urinary Distress in Women with Fibromyalgia — PMC
• Health-related quality of life in patients with IC/BPS and frequently associated comorbidities — PMC
• Interstitial Cystitis — Elucidation of Psychophysiologic and Autonomic Characteristics (ICEPAC Study) — PMC
• Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis — ClinicalTrials.gov NCT04734106
• Trial to investigate efficacy of aloe vera in patients with interstitial cystitis — Urology Times